PBYI Stock: Setting up to Stage an Advance Puma Biotechnology Inc (NYSE:PBYI) stock staged quite an advance in May 2017 as investors' concerns about poor earnings results were cast away after some positive news. The U.S. Food and Drug Administration (FDA) approved the company's "Neratinib" drug for the treatment of breast cancer. From trough to peak, PBYI stock ran up to the tune of 224.52% before the share price finally decided to take a breather. The timing of this surge toward higher prices c...
PBYI Stock: Setting up to Stage an Advance Puma Biotechnology Inc (NYSE:PBYI) stock staged quite an advance in May 2017 as investors' concerns about poor earnings results were cast away after some positive news. The U.S. Food and Drug Administration (FDA) approved the company's "Neratinib" drug for the treatment of breast cancer. From trough to peak, PBYI stock ran up to the tune of 224.52% before the share price finally decided to take a breather. The timing of this surge toward higher prices c...
Share this Article
Recommended